May 2007 in “The Journal of Urology” Finasteride lowers PSA levels in men, certain factors increase testicular cancer risk, and current guidelines for penile cancer may lead to unnecessary surgeries.
April 2012 in “The Journal of Urology” PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.
9 citations
,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
March 2009 in “The Journal of Urology” Low dose finasteride causes only small changes in PSA levels in older men with BPH.
February 2007 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Taking 1mg of finasteride daily for hair loss can lower PSA levels by 40-50%, so to keep PSA effective as a cancer screening tool, the PSA value should be doubled during treatment.
3 citations
,
May 2014 in “Urologia Journal” 5ARIs lower PSA levels, but other tests are needed to avoid missing aggressive prostate cancer.
March 2026 in “European Urology Focus” Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.
1 citations
,
June 2010 in “Mayo Clinic Proceedings” The conclusion is that individualized treatment and proper medication use are crucial in men's health, with specific recommendations for ED, BPH, and prostate cancer management.
January 2022 in “Skin appendage disorders” Finasteride is effective for male hair loss, but it may cause fertility issues, mental health problems, and rarely, breast growth. Regular health checks can reduce the risk of prostate cancer. Patient understanding and involvement in treatment is important.
20 citations
,
June 2007 in “Recent Patents on Endocrine, Metabolic & Immune Drug Discovery” Certain inhibitors can potentially treat prostate cancer and other hormone-dependent conditions by controlling sex hormone levels in cells.
July 2025 in “Journal of Education Health and Sport” Androgenetic alopecia may indicate higher risk for certain diseases and mental health issues.
May 2011 in “Expert Review of Endocrinology & Metabolism” Breast cancer survivors may have a higher risk of falls, tamoxifen could prevent breast cancer and deaths, new guidelines urge caution with prostate cancer therapy, and early balding in men may indicate a higher prostate cancer risk.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
54 citations
,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
December 2006 in “Lancet Oncology” The document concludes that better training and education are needed for proper cancer screening and criticizes the GMC's inaction as harmful to clinical ethics in the UK.
August 2011 in “Der Urologe” 5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.
March 2014 in “Hair transplant forum international” Hair transplant surgeons should also focus on their patients' overall health, including regular check-ups and screening for common health issues.
February 2007 in “Journal watch” Low-dose finasteride lowers PSA levels, which can make prostate cancer harder to detect.
October 2006 in “Aging Health” Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.
March 2011 in “Cancer Epidemiology Biomarkers & Prevention” SLCO genes may predict prostate cancer mortality risk, and lifestyle changes improve health in advanced prostate cancer.
January 2009 in “The Hastings Center Report” Finasteride reduces prostate cancer risk but may increase high-grade cancer risk.
September 2013 in “Cancer Discovery” Finasteride is safe for long-term use in prostate cancer treatment.
1 citations
,
October 2009 in “Cancer Epidemiology Biomarkers & Prevention” Cancer prevention is crucial, with a focus on research and improved screening methods.
23 citations
,
July 1993 in “Pharmacotherapy” Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.
November 2004 in “Oncology Times” Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
12 citations
,
December 2013 in “The Journal of Urology” Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.
1 citations
,
May 2001 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.
28 citations
,
January 2003 in “Urologic oncology” Suppressing certain hormones might help prevent prostate cancer.
18 citations
,
March 2009 in “Medical Hypotheses” The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.